Diabetes and Psoriasis: Different Sides of the Same Prism

References

• National diabetes statistics report, 2020. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2020. Available from: https://www.cdc.gov/diabetes/library/features/diabetes-stat-report.html. Accessed April 20, 2020.
   Google Scholar
• Schwartz SS, Epstein S, Corkey BE, et al. A unified pathophysiological construct of diabetes and its complications. Trends Endocrinol Metab. 2017;28(9):645–655.
   PubMed Web of Science ®Google Scholar
• de la Monte SM. Insulin resistance and neurodegeneration: progress towards the development of new therapeutics for Alzheimer’s disease. Drugs. 2017;77(1):47–65.
   PubMed Web of Science ®Google Scholar
• Schwartz SS, Grant SFA, Herman ME. Intersections and clinical translations of diabetes mellitus with cancer promotion, progression and prognosis. Postgrad Med. 2019;131(8):597–606.
   PubMedGoogle Scholar
• Schwartz SS, Epstein S, Corkey BE, Grant SFA, Gavin JR, Aguilar R. The time is right for a new classification system for diabetes: rationale and implications of the β-cell-centric classification schema. Diabetes Care. 2016;39(2):179–186.
   PubMed Web of Science ®Google Scholar
• Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76(3):377–390.
   PubMed Web of Science ®Google Scholar
• National Psoriasis Foundation. Statistics; 2019. Available from: https://www.psoriasis.org/content/statistics. Accessed April 20, 2020.
   Google Scholar
• Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013;149(1):84–91.
   PubMed Web of Science ®Google Scholar
• Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk factors for the development of psoriasis. Int J Mol Sci. 2019;20(18):pii: E4347.
   Google Scholar
• Mamizadeh M, Tardeh Z, Azami M. The association between psoriasis and diabetes mellitus: a systematic review and meta-analysis. Diabetes Metab Syndr. 2019;13(2):1405–1412.
   PubMed Web of Science ®Google Scholar
• Wan MT, Shin DB, Hubbard RA, Noe MH, Mehta NN, Gelfand JM. Psoriasis and the risk of diabetes: a prospective population-based cohort study. J Am Acad Dermatol. 2018;78(2):315–322.e1.
   PubMed Web of Science ®Google Scholar
• Wang H, Wang Z, Rani PL, et al. Identification of PTPN22, ST6GAL1 and JAZF1 as psoriasis risk genes demonstrates shared pathogenesis between psoriasis and diabetes. Exp Dermatol. 2017;26(11):1112–1117.
   PubMedGoogle Scholar
• Mishra R, Chesi A, Cousminer DL, et al. Relative contribution of type 1 and type 2 diabetes loci to the genetic etiology of adult-onset, non-insulin-requiring autoimmune diabetes. BMC Med. 2017;15(1):88.
   PubMedGoogle Scholar
• Quaranta M, Burden AD, Griffiths CEM, et al. Differential contribution of CDKAL1 variants to psoriasis, Crohn’s disease and type II diabetes. Genes Immun. 2009;10(7):654–658. doi:10.1038/gene.2009.51
   PubMedGoogle Scholar
• Granata M, Skarmoutsou E, Trovato C, Rossi GA, Mazzarino MC, D’Amico F. Obesity, type 1 diabetes, and psoriasis: an autoimmune triple flip. Pathobiology. 2017;84(2):71–79.
   PubMed Web of Science ®Google Scholar
• Ruan Q, Wang T, Kameswaran V, et al. The microRNA-21-PDCD4 axis prevents type 1 diabetes by blocking pancreatic beta cell death. Proc Natl Acad Sci U S A. 2011;108(29):12030–12035.
   PubMed Web of Science ®Google Scholar
• Davidovici BB, Sattar N, Prinz JC, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130(7):1785–1796.
   PubMed Web of Science ®Google Scholar
• Hu Y, Zhu Y, Lian N, Chen M, Bartke A, Yuan R. Metabolic syndrome and skin diseases. Front Endocrinol (Lausanne). 2019;10.
   Google Scholar
• Zeng J, Luo S, Huang Y, Lu Q. Critical role of environmental factors in the pathogenesis of psoriasis. J Dermatol. 2017;44(8):863–872.
   PubMed Web of Science ®Google Scholar
• Khazrai YM, Defeudis G, Pozzilli P. Effect of diet on type 2 diabetes mellitus: a review. Diabetes Metab Res Rev. 2014;30(S1):24–33.
   PubMedGoogle Scholar
• Holst JJ, Vilsbøll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol. 2009;297(1–2):127–136.
   PubMed Web of Science ®Google Scholar
• Gyldenløve M, Vilsbøll T, Zachariae C, Holst JJ, Knop FK, Skov L. Impaired incretin effect is an early sign of glucose dysmetabolism in nondiabetic patients with psoriasis. J Intern Med. 2015;278(6):660–670.
   PubMedGoogle Scholar
• Polic MV, Miskulin M, Smolic M, et al. Psoriasis severity—a risk factor of insulin resistance independent of metabolic syndrome. Int J Environ Res Public Health. 2018;15(7):1486.
   PubMedGoogle Scholar
• Rodríguez-Zúñiga MJM, García-Perdomo HA. Systematic review and meta-analysis of the association between psoriasis and metabolic syndrome. J Am Acad Dermatol. 2017;77(4):657–666.e8.
   PubMed Web of Science ®Google Scholar
• Gui XY, Yu XL, Jin H-Z, Zuo YG, Wu C. Prevalence of metabolic syndrome in Chinese psoriasis patients: a hospital-based cross-sectional study. J Diabetes Investig. 2018;9(1):39–43.
   PubMed Web of Science ®Google Scholar
• Jensen P, Skov L. Psoriasis and obesity. Dermatology. 2016;232(6):633–639.
   PubMed Web of Science ®Google Scholar
• Kong Y, Zhang S, Wu R, et al. New insights into different adipokines in linking the pathophysiology of obesity and psoriasis. Lipids Health Dis. 2019;18(1):171.
   PubMedGoogle Scholar
• Zorena K, Jachimowicz-Duda O, Ślęzak D, Robakowska M, Mrugacz M. Adipokines and obesity. Potential link to metabolic disorders and chronic complications. Int J Mol Sci. 2020;21(10):3570.
   PubMed Web of Science ®Google Scholar
• Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–1695.
   PubMed Web of Science ®Google Scholar
• Boehncke WH. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Front Immunol. 2018;9:579.
   PubMed Web of Science ®Google Scholar
• Mosca S, Gargiulo P, Balato N, et al. Ischemic cardiovascular involvement in psoriasis: a systematic review. Int J Cardiol. 2015;178:191–199.
   PubMed Web of Science ®Google Scholar
• Nasrin GM, Mohammed T, Nigel JC. Double trouble: psoriasis and cardiometabolic disorders. Cardiovasc J Afr. 2018;29(3):189–194.
   PubMedGoogle Scholar
• Trafford AM, Parisi R, Kontopantelis E, Griffiths CEM, Ashcroft DM. Association of psoriasis with the risk of developing or dying of cancer: a systematic review and meta-analysis [published online ahead of print, 2019 Oct 16]. JAMA Dermatol. 2019;155(12):1390–1403.
   PubMed Web of Science ®Google Scholar
• García-Molina L, Lewis-Mikhael AM, Riquelme-Gallego B, Cano-Ibáñez N, Oliveras-López MJ, Bueno-Cavanillas A. Improving type 2 diabetes mellitus glycaemic control through lifestyle modification implementing diet intervention: a systematic review and meta-analysis. Eur J Nutr. 2020;59(4):1313–1328.
   PubMed Web of Science ®Google Scholar
• Kirwan JP, Sacks J, Nieuwoudt S. The essential role of exercise in the management of type 2 diabetes. Cleve Clin J Med. 2017;84(7 Suppl 1):S15–S21.
   PubMedGoogle Scholar
• Ko SH, Chi CC, Yeh ML, Wang SH, Tsai YS, Hsu MY. Lifestyle changes for treating psoriasis. Cochrane Database Syst Rev. 2019;7(7):CD011972.
   PubMedGoogle Scholar
• Al-Badri MR, Azar ST. Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis. Ther Adv Endocrinol Metab. 2014;5(2):34–38.
   PubMedGoogle Scholar
• Malhotra A, Shafiq N, Rajagopalan S, Dogra S, Malhotra S. Thiazolidinediones for plaque psoriasis: a systematic review and meta-analysis. Evid Based Med. 2012;17(6):171–176.
   PubMedGoogle Scholar
• Badr D, Kurban M, Abbas O. Metformin in dermatology: an overview. J Eur Acad Dermatol Venereol. 2013;27(11):1329–1335.
   PubMedGoogle Scholar
• Glossmann H, Reider N. A marriage of two “Methusalem” drugs for the treatment of psoriasis?: arguments for a pilot trial with metformin as add-on for methotrexate. Dermatoendocrinol. 2013;5(2):252–263.
   PubMedGoogle Scholar
• Brauchli YB, Jick SS, Curtin F, Meier CR. Association between use of thiazolidinediones or other oral antidiabetics and psoriasis: a population based case-control study. J Am Acad Dermatol. 2008;58(3):421–429.
   PubMedGoogle Scholar
• Barra L, Pope JE, Payne M. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire. J Rheumatol. 2009;36(7):1421–1428.
   PubMedGoogle Scholar
• Pina T, Armesto S, Lopez-Mejias R, et al. Anti-TNF-α therapy improves insulin sensitivity in non-diabetic patients with psoriasis: a 6-month prospective study. J Eur Acad Dermatol Venereol. 2015;29(7):1325–1330.
   PubMedGoogle Scholar
• Rigby MR, Harris KM, Pinckney A, et al. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest. 1205;125(8):3285–3296.
   Google Scholar